tbuckley/cabot-search huggingface dataset:
Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma.
Authors: Steven Attia, Seth Pollack, Brian Andrew Van Tine, Sant P. Chawla, Mihaela Druta, Melissa Amber Burgess, Gerry C. Bohac, Neeta Somaiah
Journal: Journal of Clinical Oncology (2019)

e22520 Background: Outcomes of patients (pts) with advanced synovial sarcoma (SS) and myxoid/round cell sarcoma (MRCL) is lacking. Current data is limited to single institution studies or post hoc analyses of clinical trials. To understand the natural history of these subtypes of soft tissue sarcoma we performed a systematic analysis of SS and MRCL patients from large medical institutions. Methods: Data was abstracted at 7 U.S. centers for pts treated from 2005 to 2015. Advanced SS or MRCL were eligible if they had received chemotherapy and were 18 years or older. The primary endpoint was overall survival, and secondary endpoints were progression free survival, time to next treatment, time to new distant metastasis. Results: 350 pts with locally advanced (LA), unresectable and/or or metastatic (Met) SS (n = 249) and MRCL (n = 101) were analyzed. The median age at diagnosis was 40 years for SS pts (58.2% male). The median age of MRCL pts was 50 years (67.3% male). 249 SS pts all had ≥ 1line of therapy, 74.7% had ≥2 lines of treatment. All MRCL pts received ≥1 line of treatment, 72.3% had ≥2 lines. The clinical outcomes (median overall survival (OS), progression free survival (PFS), time to next treatment (TTNT) and time to distant metastasis (TTDM)) from start of first-line chemotherapy are: The OS and PFS from second line chemotherapy decreased for all evaluable pts (n = 259) was 17.9 months (mos) [95% confidence interval (CI) (15.0, 22.3)]; 3.9 mos (3.4, 4.8), respectively. A similar trend toward shortened OS and PFS were seen with each subsequent line of chemotherapy. Conclusions: This registry analyzing real-world clinical outcomes among advanced SS and MRCL pts is the most comprehensive performed to date. It provides data on clinical outcomes depending on line of therapy and can provide the backbone for better patient management and design of future clinical trials.[Table: see text]
Abstract 15586: Optimum Heart Rate Response to Autonomic Regulation Therapy is Frequency Dependent
Authors: Jeffrey L Ardell, Heath Nier, Chris L Ardell, Badri Amurthur, Eric Beaumont, Elizabeth M Southerland, Bruce H KenKnight, John A Armour
Journal: Circulation (2013)

Background: Cervical vagus nerve stimulation (VNS) elicits beneficial central and peripheral cardiovascular effects; such responses being sub-served by activation of ascending afferent and descending efferent projections. However, optimal VNS parameters required to elicit beneficial neuronal stabilizing effects on regional cardiac function have not been determined. Methods: Normal canines (n=4) were implanted with VNS devices on the right cervical vagus nerve and programed to deliver chronic, intermittent stimulation (14 s ON, 66 s OFF). Holter monitors recorded ECG continuously for 24 hours during various combinations of stimulation frequency (5, 10, and 20 Hz) and pulse widths (250 and 500 μs). VNS amplitude (mA) was programmed to the cardiac response threshold (a 10% acute decrease in heart rate during VNS); it averaged 1.75 mAmp. Results: Chronic right-sided VNS elicited a modest reduction in heart rate and an increase in heart rate variability at 5 and 10 Hz, but not 20 Hz. The magnitude of the cardi...
P13.15 DNA methylation abnormalities in non-promoter regulatory regions are associated with invasive behavior in pituitary tumors
Authors: M Q S Mosella, T S Sabedot, T M Malta, J Rock, M Felicella, T Aho, H Noushmehr, A V Castro
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Despite histologically benign, pituitary tumors (PT) may invade important adjacent neurovascular structures which can incur in significant comorbidities preventing a complete surgical resection and contributing to resistance to medical treatment. DNA methylation clearly stratified PT based on their functional status i.e. nonfunctioning PTs (NFPTs) from functioning PT (FPTs). However associations of methylation aberrations with invasive behavior is less clear. MATERIAL AND METHODS In order to evaluate whether DNA methylation alterations in regulatory regions other than promoter and coding regions are associated with invasive behavior we performed a meta-analysis of the genome-wide methylome of three public available PT cohorts plus our own (Illumina HumanMethylation platforms- 450K/EPIC). Pituitary specimens comprised of 43 invasive pituitary tumors (InvPT) and 37 noninvasive (NInvPT); 12 FPT and 68 NFPTs, in addition to 20 non-tumor pituitaries. RNA-seq data were available for one cohort (n=23, 12 InvPT,11NInvPT) and integrated with DNA methylation. Invasiveness criteria was based on Knosp grade &gt;= 2 and/or sphenoid or dural invasion. RESULTS Wilcoxon Rank-sum test; Δβ=0.15; p-value &lt;0.001 identified 58 differentially methylated CpG sites in InvPT that were mainly hypomethylated (95%) in relation to NInvPT. NInvPT methylation profile was similar to non-tumor specimens, despite its heterogeneity. Thirty-four percent (n=20) of the differentially methylated CpG sites were located within predicted enhancer regions distributed in intronic (40%), intergenic (40%) and promoter (20%) regions. Predicted enhancer-target genes were enriched for actin filament cell movement, response to starvation, growth factor stimulus and protein autophosporilation pathways. Among them, ZNF625 and INO80E were found mostly negative correlated among methylation and expression data (-0.50 and -0.48, respectively), besides DOC2A found to be one potentially differentially expressed gene under enhancer control (log2FC &gt; 0.2, pvalue &lt;0.05). CONCLUSION Our results suggest that methylation alterations in predicted regulatory regions, such as enhancers, annotated in non-promoter regions (introns and intergenic) may contribute to the invasive behavior of PT.
Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS).
Authors: Margaret von Mehren, Samuel Litwin, Vinod Ravi, Scott Schuetze, Sujana Movva, Mark Agulnik, Andrew S. Kraft, Eric Daniel Tetzlaff, Neeta Somaiah
Journal: Journal of Clinical Oncology (2019)

11039 Background: AS is a rare aggressive soft tissue sarcoma derived from endothelial cells. It can occur as cutaneous or visceral disease, be associated with chronic lymphedema, or arise after radiation therapy. Non-metastatic AS has a poor overall 5-year survival rate of 27-35%; improved treatments are needed. We hypothesized that P would have therapeutic activity in AS because of the agent’s anti-angiogenic activity. Methods: This was an open label, multi-institutional trial of P using a Simon two-stage design. The primary endpoint was to determine the PFS at 3 months and response rate defined as CR and PR in AS treated with P. Eligibility criteria included incurable AS, age≥18, adequate blood counts, cardiac, hepatic and renal function, RECIST measurable disease, ability to swallow pills and provide informed consent. P was given as 400 mg orally twice daily, with ongoing disease assessment every 8 weeks. Results: From 11/2011 - 12/2018, Twenty-nine patients were treated on study (Table; data available for 28 patients). 50% were female and 55% had cutaneous disease. Eight patients were inevaluable for response: 3 never started P (lab abnormalities day 1, n=1; consent withdrawal, n=2); 4 due to toxicity, 1 for non-compliance. As of 12/15/18, best response was SD seen in 12 patients. The 3-month PFS rate determined by Kaplan-Meyer estimate was 54.6% (95%CI 36.0, 82.9%). SD was seen in 25% (4/16) with cutaneous disease and 8.3% (1/12) with visceral disease. Toxicities were manageable and similar to prior reports. Grade 3/4 toxicities included hypokalemia, increased U/P ration, lymphocytopenia, hypertension and abnormal LFTs; there was one death due to cardiac arrest considered possibly related to P. Conclusions: Accrual rate was slower than expected possibly because P was available off-study. Treatment was feasible and did not reveal any previously unreported toxicities. Efficacy outcomes were limited by early withdrawal of patients. No RECIST responses were observed; however P has a clinically meaningful 3-month PFS, primarily in cutaneous AS. Clinical trial information: NCT01462630. [Table: see text]
Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple Myeloma
Authors: Vassilis Koutoulidis, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Flora Zagouri, Ioanna Klapa, Andriani Boultadaki, Maria Gavriatopoulou, Sophia Fontara, Eftathios Kastritis, Meletios A. Dimopoulos, Lia A. Moulopoulos
Journal: Blood (2017)
P06.02 Tumor Treating Fields therapy application in 3-year-old grade 4 glioma patient is feasible and safe
Authors: S Kietz, M Stein
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND High-grade gliomas (HGG) are aggressive brain tumors affecting both children and adults. In adult patients a new treatment modality was recently established for patients with newly diagnosed (nd) and recurrent glioblastoma (GBM). Low intensity intermediate frequency alternating electric fields, known as Tumor Treating Fields (TTFields), demonstrated significantly increased survival rates in combination with adjuvant temozolomide (TMZ) in adult ndGBM patients. For pediatric HGG patients only few treatment options are available. Here, we report on a pediatric patient who is receiving TTFields therapy in combination with temozolomide. MATERIAL AND METHODS A three-year-old male presented with a grade IV glioma with H3K27M expression located pontine on the right occipital. A stereotactic biopsy was performed; further analysis revealed no IDH1 mutation, no TERT promoter mutation and no MGMT promoter methylation. The patient recieved radiochemotherapy with temozolomide. TTFields therapy was initiated after completion of radiochemotherapy in combination with temozolomide. Due to the location of the tumor, the infratentorial transducer array layout was used for TTFields application. RESULTS At the beginning of TTFields therapy the patient and his family needed time to get used to the new therapy, due to this the adherence to TTFields therapy was on a low level in the first month. The TTFields usage rate improved every month from about 40 % in the first two months to about 80 % after 5 and 6 months. After the initial time for adaption to the therapy, the average usage rate in months 4 to 8 was 75.87 %, which is above the independent prognostic threshold of 75 %. The patient is on TTFields therapy for more than 8 months and no therapy-related adverse events were observed during this time. To-date the patient is still on TTFields therapy and clinically stable. MRI analysis revealed stable disease with a slightly reduced area of contrast-enhancement. CONCLUSION In this case, the TTFields usage rate was low in the beginning, the patient and his relatives demonstrated a successful adaption to the therapy over time. This case demonstrates that TTFields therapy can be continued at high adherence, although the usage rate might be low in the beginning. Moreover, in this presented patient TTFields therapy is feasible and safe in a pediatric patient at 3 years of age at initiation of therapy. In conclusion, TTFields therapy can be offered to pediatric patients with HGG. Safety and efficacy in pediatric patients should be further investigated in clinical trials.
Intra-arterial infusion of irinotecan loaded microparticles (IAIRIM) for symptomatic and unresectable colorectal cancer (UCRC): Preliminary report.
Authors: Simone Comelli, Roberto Bini, Giacomo Gallo, Daniele Savio, Tiziana Viora, Giacomo Paolo Vaudano, Renzo Leli
Journal: Journal of Clinical Oncology (2013)

e20562 Background: We evaluated feasibility, safety and efficacy of IAIRIM on a compassionate use basisto treat locally UCRC and investigated a volume reduction of the target lesion. Methods: We considered patients with UCRC not eligible for any conventional treatment presenting severe anemia from rectal bleeding, colon obstruction and severe pain. A multidisciplinary evaluation was performed by surgeon, radiologist and oncologist. Patients underwent abdominal quadriphasic CT scan, in order to obtain a preliminary arterial mapping of the tumour; colostomy was performed in all patients. Angiography of superior and inferior mesenteric arteries was obtained to define the lesion vascularization and perform IAIRIM. A month later a new CT scan evaluation was performed to evaluate the volume of the target on Aw Volume share 2 (slice thickness 5mm). We defined the results adopting MASS, RECIST and mChoi response criteria. QoL was reported adopting Edmonton scale and EORTC QLQ-C30. Results: Ten patients were enrolled, IAIRIM was successfully performed in all without major complications. Ten patients experienced a clinical improvement with disappearance of bleeding and reduction of pain in a week. Fever lasting 36 hours (24-48) and minimal discomfort procedure related in were observed in all . Reduced but persisting muchorrea and tenesm were reported in 4 patient. After four months all patients were alive without pain or bleeding. 8/10 patients experienced mass reduction ( -39%; range -96% / +7%) and 2/10 no evidence of progression. QoL: Edmonton scale (considering only pain, fatigue, well-being and depression items) was around 7 in 8/10 patients before treatment and 6 in 2/10 patients. After treatment 6/10 patients reported mean score 3; 3/10 reported 4, 1/10 reported 2. Using EORTC QLQ-C30, mean score decreased from 3 to 2. Conclusions: IAIRIM seems feasible, with low side effects in patients bearing UCRC considered out of usual approaches. A reduction of symptomatic treatments and an increase of QoL (Edmonton and EORT QLQ-C30 scale) has been recorded in all patients. Volume reduction of the tumour has been observed in nine patients. Further experiences are warranted.
Biomarkers, single nucleotide polymorphisms and cardiovascular risk after acute myocardial infarction : observations from the Osaka Acute Coronary Insufficiency Study (OACIS)
Authors: Y Sakata, Masahiko Shimizu, Shinichiro Suna, Masaya Usami, Sen Matsumoto, Hiroya Mizuno, Yasunori Ueda, Hiroshi Ito, Shinsuke Nanto, Masatsugu Hori, Hiroshi Sato
Journal: Circulation (2009)
OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults
Authors: T Picart, M Barritault, E Tabouret, A Idbaih, C Izquierdo Gracia, D Poncet, J Honnorat, D Meyronet, J Guyotat, F Ducray
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND H3 G34-mutant high-grade gliomas occur primarily in children but can also be encountered in adults. The aim of the present study was to describe the characteristics of H3 G34-mutant high-grade gliomas in adults. MATERIAL AND METHODS We analysed the characteristics of 17 adult H3 G34-mutant high-grade gliomas and compared them with those of adult grade IV gliomas with H3 K27M mutation (n=21), IDH mutation (n=42) and TERT promoter (pTERT) mutation (n=88). RESULTS Median age at diagnosis in H3 G34-mutant gliomas was 25 years (range: 19–33 y). All tumors had a hemispheric location. The radiological presentation was suggestive of a high-grade glioma in 6 patients but in 10 patients it initially suggested another diagnosis due to absent or faint contrast enhancement (n=9) or the presence of an initial intratumoral haemorrhage (n=1). In non- or faint contrast-enhancing cases, diffusion-weighted imaging (DWI) was more helpful to suspect an aggressive tumor than MR spectroscopy and perfusion MRI. All H3 G34-mutant gliomas were classified as IDH wildtype glioblastomas. PNET-like foci were observed in 8 cases and most cases were immunonegative for ATRX (92%) and Olig2 (81%) and demonstrated MGMT promoter methylation (82%). The clinical, radiological and histological presentation of H3 G34-mutant gliomas was different from that of midline H3 K27M-mutant diffuse gliomas and from that of IDH-mutant and IDH-wildtype pTERT-mutant glioblastomas. Median overall survival of G34-mutant gliomas was 23.9 months compared to 19.6 months (p=0.16), 13.7 months (p=0.45) and 58 months (p=2.3x10-10) in H3 K27M-mutant diffuse gliomas, IDHwt pTERT-mutant and IDH-mutant glioblastomas, respectively. CONCLUSION Adults H3 G34-mutant high-grade gliomas are associated with distinct characteristics and a poor prognosis. DWI seems helpful to identify cases that present as non-contrast enhancing lesions and can wrongly suggest another diagnosis in these young patients.
Patient Characteristics and Adenoma Detection Rates
Authors: Richard L. Kravitz
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P03.08 Large cerebral arteriovenous malformations management with Volume-staged gamma knife radiosurgery
Authors: R M Emad Eldin, W A Reda, A M El-Shehaby, K Abdel Karim, A Nabeel, S Tawadros
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Large cerebral arteriovenous malformations (AVM) pose a management dilemma because of the limited success of any single treatment modality by itself. Surgery alone is associated with significant morbidity and mortality. Similarly, embolization alone has limited efficacy. Volume-staged gamma knife radiosurgery (VSGR) has been developed for the treatment of large AVMs, to increase the efficacy and improve safety of treatment of these lesions. The aim of the study was to assess the efficacy and safety of VSGR technique for the treatment of large cerebral AVMs. METHODS The study included patients treated by VSGR between May 2009 and July 2015. All cases had large AVMs (&gt;10 cc). These were 29 patients. RESULTS Twenty-four patients completed radiographic follow up with 15 obliteration cases (62.5%). There was a total of 56 sessions performed. The mean AVM volume was 16 cc (10.1–29.3 cc). The mean prescription dose was 18 Gy (14–22 Gy). The mean follow up duration was 43 months (21–73 months). One patient died during follow up from unrelated cause. Two cases suffered haemorrhage during follow up. Symptomatic edema developed in 5 (17%) patients. The factors affecting obliteration were smaller total volume, higher dose/stage, non-deep location, compact AVM, AVM score less than 3, &gt;18 Gy dose and &lt;15 cc total volume. The factors affecting symptomatic edema were smaller total volume and shorter time between first and last sessions (p 0.012). T2 image changes were affected by SM grade 3 or more (p 0.013) and AVM score 3 or more (p 0.014). CONCLUSION VSGR provides an effective and safe treatment option for large cerebral AVMs. Smaller AVM volume is associated with higher obliteration rate.
Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy
Authors: Emir Hadzijusufovic, Gregor Hoermann, Susanne Herndlhofer, Wolfgang R. Sperr, Bernd Jilma, Gerit H. Schernthaner, Peter Valent
Journal: Blood (2017)
The Long View on Childhood Lead Poisoning
Authors: Thomas Schlenker
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Creation of a long-acting rilpivirine prodrug nanoformulation
Authors: James R. Hilaire, Aditya N. Bade, Brady Sillman, Nagsen Gautam, Jonathan Herskovitz, Bhagya Laxmi Dyavar Shetty, Melinda S. Wojtkiewicz, Adam Szlachetka, Benjamin G. Lamberty, Sruthi Sravanam, Howard S. Fox, Yazen Alnouti, Prasanta K. Dash, JoEllyn M. McMillan, Benson J. Edagwa, Howard E. Gendelman
Journal: Journal of Controlled Release (2019)